Edgewise Therapeutics (EWTX) Change in Acquisitions & Divestments (2021 - 2026)

Edgewise Therapeutics has disclosed Change in Acquisitions & Divestments across 6 years of filings, most recently posting $4.0 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $4.0 million, down 97.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $280.2 million (up 158.9% YoY), and the FY2025 annual result was $427.3 million, up 2605.51% from the prior year.
• Change in Acquisitions & Divestments came in at $4.0 million for Q1 2026 at Edgewise Therapeutics, down from $375.9 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $375.9 million in Q4 2025 to a low of -$258.3 million in Q4 2023.
• The 5-year median for Change in Acquisitions & Divestments is $59.8 million (2022), against an average of $39.1 million.
• Across the five-year window, Change in Acquisitions & Divestments slumped 469.69% in 2023 and surged 12126.94% in 2025, its largest moves.
• Edgewise Therapeutics' Change in Acquisitions & Divestments stood at $69.9 million in 2022, then plunged by 469.69% to -$258.3 million in 2023, then jumped by 101.19% to $3.1 million in 2024, then soared by 12126.94% to $375.9 million in 2025, then sank by 98.94% to $4.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $4.0 million (Q1 2026), $375.9 million (Q4 2025), and -$177.7 million (Q3 2025), per Business Quant data.